Vertex announces UK approval for CASGEVY™
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCo-founder and principal Dan Littlefield spoke on Modality Solutions’ involvement in the Ebola clinical trials with Executive Platforms for its popular EP Thought Leader Series. Most recently Dan worked with the NIH to help fight Ebola in the Democratic Republic of Congo.
Dan talks about some of the challenges of working in a conflict environment, and how Modality Solutions’ experience designing and implementing cold chain solutions to assure patient safety and drug efficacy contributed to the success of the Ebola virus clinical trial. “Our work in the Congo, along with our earlier work in Sierra Leone, Liberia, and Guinea, has been effective in ensuring clinical trial successes by applying effective engineering tools to daunting logistical problems. We’ve been fortunate to work with many great people in our efforts,” said Dan Littlefield.
You can watch the interview below:
Source: https://epthoughtleaders.com/engineering-cold-chain-solutions-to-support-ebola-clinical-trials-a-conversation-with-dan-littlefield-of-modality-solutions/
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read DetailsCongratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read DetailsCongratulations to Iveric Bio for their FDA approval for IZERVAY™️️, a new treatment for...
read Details